Korro Bio, Inc. (KKR) scored on five pillars from its reported financial statements, and ranked against 261 Financials companies.
Korro Bio, Inc. (KKR) scores 1.8 out of 10 as of , computed from its reported financial statements. That reads as low quality. The reading rests on profitability, and predictability is what holds it back.
2 pillars, solvency and efficiency, are unscored because the filings behind them carry too little to judge. Each is shown as a dash rather than a zero, and the overall score is the weighted average of what could be scored.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
Korro Bio, Inc.’s filings do not show enough of the signs a moat leaves: 0 of 4 indicators passed.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
Korro Bio, Inc. (KKR) has a Lemma Quality Score of 1.8 out of 10 as of October 16, 2026, which reads as low quality. A low reading means the reported numbers show weakness on several pillars at once, which is a reason to understand the business before anything else. Five pillars feed it, and every one of them is computed from what the company reported rather than from its share price.
Among the 261 Financials companies with a published score, that ranks at the 2nd percentile, among the weakest quarter of its peers. For reference, the middle of the group scores 5.9 and a company needs 6.8 to reach its top quarter, which leaves Korro Bio, Inc. well below the median.
Profitability scores 2.7 out of 10, which reads as weak. The median across 255 Financials companies is 6.8, so Korro Bio, Inc. is well below its peers on this pillar and ranks at the 7th percentile. A low reading here is the first thing to explain: it is the pillar most closely tied to whether the business creates value at all.
There is no solvency score for Korro Bio, Inc.: too little of the pillar could be measured from the filings to give an honest reading. The overall is therefore the weighted average of the other pillars. Across 140 Financials companies the median for this pillar is 8.5. Without it the overall says nothing about how comfortably the company carries its debt.
On growth, Korro Bio, Inc. scores 2.3, a weak reading. Its peers have a median of 4.6 across 241 Financials companies, which places it well below them, at the 18th percentile. A low growth score is common for large, established companies and is not a verdict on quality on its own, but it limits how the business can compound.
There is no efficiency score for Korro Bio, Inc.: too little of the pillar could be measured from the filings to give an honest reading. The overall is therefore the weighted average of the other pillars. Across 211 Financials companies the median for this pillar is 5.8. Without it the overall cannot say how well reported profit turns into cash.
Predictability scores 0.0 out of 10, which reads as weak. Every other company in the group scores higher here, against a median of 4.9 across 256 Financials companies. Weak predictability means revenue or earnings have swung widely from year to year, so any single year’s figures are a less reliable guide.
The profile is uneven. Profitability leads at 2.7 while predictability trails at 0.0, a gap of 2.7 points, so the overall averages a clear strength against a clear soft spot. Leading with profitability is the most valuable kind of strength, because margins and returns are what the other pillars ultimately feed. A predictability shortfall means the record is volatile, so the averages behind the other pillars move more than they appear to.
Closing the gap on profitability would do the most for the overall. At the median of Financials companies, 6.8, Korro Bio, Inc. would score about 3.4 instead of 1.8. Only three of the five pillars could be scored. Together they carry 65 of the 100 weight points (the full set is profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and the overall is the weighted average of those alone.
These are the Financials companies closest to Korro Bio, Inc. in market value. Each has its own page scored on the same five pillars, so the comparison is like for like.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Korro Bio, Inc. scores 1.8 out of 10, which reads as low quality. Its strongest pillar is profitability, its weakest is predictability. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Korro Bio, Inc. ranks at the 2nd percentile of the 261 Financials companies Lemma publishes a score for. The median there is 5.9 and the top quarter starts at 6.8, against Korro Bio, Inc.’s 1.8.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 16, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for KKR are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card